Abstract
I have read the very interesting and informative article of Hoover et al,[1][1] which may open new avenues in treating imatinib-refractory and imatinib-sensitive chronic myeloid leukemia (CML). However, when testing the synergic potential of STI + farnesyl transferase inhibitor (FTI) combination on